OncoMed Pharma (OMED), Lilly Enter Collaboration for NSCLC Treatment
Tweet Send to a Friend
OncoMed Pharma (NASDAQ: OMED) has entered into an agreement with Eli Lilly and Company (NYSE: LLY). Demcizumab, OncoMed's anti-DLL4 antibody ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
